Just found this oddity.
Thursday, October 27 2022 9:10 AM, EST
NC Urges FDA And FTC To Investigate Potentially False Advertising Claims Made By A Recent-FDA Approved An
Targeted News Service "News Service"
WASHINGTON, Oct. 27 (TNSgov) - The National Consumers League issued the following news release and letter:
The National Consumers League (NCL) recently submitted a letter to the Food and Drug Administration (FDA) and the Feder
(FTC) urging the agencies to look into misleading advertising claims made by a recent FDA-approved anti-wrinkle drug calle
(DaxibotulinumtoxinA-lanm).
Revance Therapeutics, Inc., the manufacturer of DAXXIFY (TM), is promoting the drug's ability to reduce the appearance of f
in about half of its users for about six months. However, FDA-required labeling verifies that roughly one-third of users exper
lines for six months after injection - a 20 percent discrepancy from the company's claim.
NCL believes this discrepancy is concerning and warrants a closer investigation. Moreover, a study mentioned in the compar
appears to make inaccurate claims about its results, according to NCL.
We ask that if our concerns are warranted, the FDA and the FTC should hold Revance Therapeutics to accurate claims and in
correct anything deceptive in their advertising, says NCL Executive Director Sally Greenberg.
AI
Market Data 
Markets 
